Your Source for Venture Capital and Private Equity Financings

Massinvestor/VC News Daily

VC-funded Company:

Regenacy Pharmaceuticals
303 Wyman Street, Suite 300
Waltham, MA 02451
Phone: 617-415-5030
https://regenacy.com/

Regenacy Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company regenerating biological function by protein acetylation for the treatment of diabetic and other peripheral neuropathies and other chronic conditions. The company's selective inhibition technology provides superior safety profiles and potential enhanced efficacy compared to non-selective HDAC inhibitors. Regenacy selectively inhibits histone deacetylase 6 (HDAC6) to restore normal intracellular protein and organelle transport in peripheral neuropathies, and also has a portfolio of selective HDACs 1 and 2 inhibitors that have potential to treat major blood diseases such as leukemia, sickle cell disease, β-thalassemia, and cognitive dysfunction in neurological disorders.

Key Contact
Name
Simon Jones
Title
CEO
Funding Events

Date
Amount
Type
Investors
03/25/20 $30,000,000 Series A 3E Bioventures
Cobro Ventures
TA YA Venture Holdings
Taiwania Capital
Viva Biotech
Yonjin Capital